Erschienen in:
26.05.2020 | Original Article
Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery
verfasst von:
Yoko Oshima, Takashi Suzuki, Satoshi Yajima, Tatsuki Nanami, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada
Erschienen in:
Surgery Today
|
Ausgabe 11/2020
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To establish the clinicopathological importance of serum p53 autoantibody (s-p53-Ab) titrations in patients with gastric cancer.
Methods
Preoperative s-p53-Ab titers were analyzed in 448 gastric cancer patients between 2010 and 2017. Seropositive patients were divided into three groups based on their antibody titers: 1.31–10.0 U/mL (low group); 10.1–100 U/mL (medium group); and > 100 U/mL (high group). We evaluated the associations between the s-p53-Abs and clinicopathological factors, carcinoembryonic antigen (CEA) levels, and cancer antigen 19-9 (CA19-9) levels. Overall survival was analyzed by multivariate analyses.
Results
A total of 72 patients (16%) were positive for s-p53-Abs. The rate of positivity for s-p53-Abs + CEA + CA19-9 was significantly higher than that for CEA + CA19-9, even in stage I gastric cancers. Gender, tumor depth, lymphatic node metastases, and distant metastases were all significantly associated with the presence of s-p53-Abs; however, overall survival was not associated with the antibodies. The patients in the high titer group (> 100 U/mL) had a relatively worse survival than those in the other groups.
Conclusions
Based on our findings, s-p53-Abs improve the overall rate of positivity for detecting gastric cancer, but the prognostic value of a high s-p53-Ab titer for predicting overall survival is limited.